• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

    2/14/24 4:00:26 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email
    SC 13G/A 1 g110242sc13ga2.htm AMENDMENT NO. 2

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Altimmune, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

     

    02155H200

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 
     

     

    CUSIP No. 02155H200

    13G/A Page 2 of 9 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*


    (
    a) ¨

    (b) x

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,750,000

     

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,750,000

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,750,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

     

    11

    Percent of Class represented by amount in row 9

     

    5.1%

     

    12

    type of reporting person

     

    pN

     

     

     Page 2 of 8 
     

     

    CUSIP No. 02155H200 13G/A Page 3 of 9 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*


    (
    a) ¨

    (b) x

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,750,000

     

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,750,000

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,750,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

     

    11

    Percent of Class represented by amount in row 9

     

    5.1%

     

    12

    type of reporting person

     

    OO

     

     

     Page 3 of 8 
     

     

    CUSIP No. 02155H200

    13G/A Page 4 of 9 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*


    (
    a) ¨

    (b) x

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

     

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,750,000

     

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,750,000

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,750,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

     

    11

    Percent of Class represented by amount in row 9

     

    5.1%

     

    12

    type of reporting person

     

    IN

     

     

     Page 4 of 8 
     

     

    Item 1(a).Name of Issuer:

     

    Altimmune, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    910 Clopper Road, Suite 201S, Gaithersburg, MD 20878

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 02155H200

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)       Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 2,750,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 2,750,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 2,750,000 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 
     

     

    The percentages used herein are based on 53,728,871 shares of Common Stock outstanding as of November 3, 2023, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 7, 2023.

     

    (b)      Percent of Class:

     

    Tang Capital Partners 5.1%
    Tang Capital Management 5.1%
    Kevin Tang 5.1%

     

    (c)       Number of shares as to which such person has:

     

    (i)      sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)     shared power to vote or to direct the vote:

     

    Tang Capital Partners 2,750,000 shares
    Tang Capital Management 2,750,000 shares
    Kevin Tang 2,750,000 shares

     

    (iii)    sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)    shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 2,750,000 shares
    Tang Capital Management 2,750,000 shares
    Kevin Tang 2,750,000 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 6 of 8 
     

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

     

     

    Get the next $ALT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    More analyst ratings

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/18/25 4:15:22 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/14/25 7:27:34 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Altimmune with a new price target

    Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00

    7/10/25 8:47:17 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Altimmune

    William Blair initiated coverage of Altimmune with a rating of Mkt Perform

    2/28/25 7:17:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Altimmune with a new price target

    Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

    1/8/25 7:32:53 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Jordt Raymond M was granted 1,368 shares, increasing direct ownership by 4% to 36,270 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    8/4/25 4:06:54 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Harris Matthew Scott was granted 2,018 shares, increasing direct ownership by 14% to 16,087 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    8/4/25 4:05:50 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Roberts M Scot was granted 846 shares, increasing direct ownership by 1% to 74,066 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    8/4/25 4:05:21 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

    Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD). Fast Track designation is intended to accelerate the development and review of new drugs that target serious conditions and address unmet medical needs. RECLAIM (NCT06987513)

    8/19/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Board of Directors Appoints Jerry Durso as Chairman

    Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's

    8/11/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    SEC Filings

    View All

    SEC Form DEF 14A filed by Altimmune Inc.

    DEF 14A - Altimmune, Inc. (0001326190) (Filer)

    8/15/25 4:11:17 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Altimmune Inc.

    10-Q - Altimmune, Inc. (0001326190) (Filer)

    8/12/25 10:15:21 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Altimmune, Inc. (0001326190) (Filer)

    8/12/25 7:10:10 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Financials

    Live finance-specific insights

    View All

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

    GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R

    8/5/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

    First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

    6/26/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Board of Directors Appoints Jerry Durso as Chairman

    Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's

    8/11/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

    Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

    2/25/25 7:30:00 AM ET
    $ALT
    $DXCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

    GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun

    3/27/23 4:05:00 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/17/24 11:16:51 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/16/24 4:21:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care